BRISTOL-MYERS SQUIBB RECEIVES USE PATENT FOR "UNPATENTABLE" TAXOL: THREE-HOUR BREAST AND OVARIAN INFUSION SCHEDULE COVERED BY PATENT THAT EXPIRES IN 2012
Executive Summary
The three-hour infusion schedule for Bristol-Myers Squibb's Taxol (paclitaxel) in breast and ovarian cancer is protected by a newly issued patent that runs through 2012.
You may also be interested in...
Closing The Books On Taxol: GAO Report Fuels Sen. Wyden’s Pricing Push
NIH should consider the cost of new therapies to Medicare when negotiating technology transfers for taxpayer-funded research, Sen. Ron Wyden (D-Ore.) maintained in response to a June 4 1GAO report on the National Institutes of Health's collaboration with Bristol for the oncologic agent Taxol
Closing The Books On Taxol: GAO Report Fuels Sen. Wyden’s Pricing Push
NIH should consider the cost of new therapies to Medicare when negotiating technology transfers for taxpayer-funded research, Sen. Ron Wyden (D-Ore.) maintained in response to a June 4 1GAO report on the National Institutes of Health's collaboration with Bristol for the oncologic agent Taxol
Bristol/FTC Settlement Brings PTO Standards Into Spotlight
The Federal Trade Commission's antitrust settlement with Bristol-Myers Squibb may bring Patent & Trademark Office standards for pharmaceutical patents into the spotlight